Special Issue

Personalized Pain Medicine: Biomarkers and New Therapeutic Frontiers

Message from the Guest Editor

Chronic pain remains one of the most complex and debilitating conditions in medicine, affecting millions worldwide. Despite advances in pharmacological and interventional therapies, the heterogeneity of pain disorders poses a significant challenge for effective treatment. In recent years, the emergence of personalized pain medicine has opened new avenues for precision diagnosis and tailored interventions. This Special Issue aims at exploring the role of biomarkers in pain medicine and their potential to transform patient management. By integrating molecular. neurophysiological, and imaging biomarkers, clinicians and researchers can move beyond the traditional trialand-error approach, improving both efficacy and safety in pain treatment. We welcome contributions on cuttingedge research covering topics such as novel biomarkers for pain phenotyping, genetic and epigenetic insights, neuroimaging advances, and Aldriven predictive models. Additionally, studies on the clinical application of biomarkers in personalized interventions, pharmacogenomics, and non-invasive monitoring are of particular interest.

Guest Editor

Dr. Gustavo Fabregat-Cid

- 1. Multidisciplinary Pain Management Department, General University Hospital Consortium of Valencia, 46014 Valencia, Spain
- 2. Pain Management Department, Ascires Hospital, 46004 Valencia, Spain
- 3. Clinical Anesthesiology, University of Valencia, 46010 Valencia, Spain

Deadline for manuscript submissions

30 November 2025



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/232292

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

